Lipidor AB (publ) (STO:LIPI)

Market Cap	174.88M
Revenue (ttm)	5.85M
Net Income (ttm)	-13.81M
Shares Out	813.40M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,700,110
Average Volume	12,704,968
Open	0.2395
Previous Close	n/a
Day's Range	0.2150 - 0.2685
52-Week Range	0.0400 - 0.5000
Beta	0.68
RSI	32.15
Earnings Date	May 9, 2025

About Lipidor AB

Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-in...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2009
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: LIPI

Financial Performance

In 2024, Lipidor AB's revenue was 5.85 million, an increase of 6618.39% compared to the previous year's 87,000. Losses were -13.81 million, 20.2% more than in 2023.